ServiziMenu principale

<< Torna a "Tutti gli studi"

MK-3475-01A - KEYMAKER-U01 Substudy 1: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents With Pembrolizumab in Combination With Chemotherapy in Treatment-Naive Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Studio Clinico

Patologia: Neoplasie del polmone

Osservazionale-Sperimentale: Sperimentale

Monocentrico-Multicentrico: Multicentrico

Randomizzato: No

Fase di studio: II

Richiesta mandatoria di tessuto: 

Linee di trattamento: Prima linea

Criteri di inclusione: 

- Has histologically - or cytologically - confirmed diagnosis of Stage IV squamous or nonsquamous NSCLC
- Participants with nonsquamous NSCLC who are not eligible for an approved targeted therapy
- Is able to to provide archival tumor tissue sample collected either within 5 years or within the interval from completion of last treatment but before entering the screening period or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated obtained within 90 days of treatment initiation
- Has not received prior systemic treatment for their metastatic NSCLC
- Is able to complete all screening procedures within the 35-day screening window
- Has adequate organ function within 10 days of initiation of study treatment
- Male participants must agree to use contraception and should refrain from donating sperm during the treatment period and:
    - Substudy 1: for at least 120 days after the last dose of pembrolizumab and for at least 180 days after the last dose of chemotherapy
    - Substudies 2 and 3: for at least 120 days after study treatments
- Female participants must not be pregnant or breastfeeding, and at least 1 of the following conditions apply:
    - Not a woman of childbearing potential (WOCBP), OR
    - A WOCBP who agrees to use contraception during the treatment period and:
        - Substudy 1: for at least 120 days after the last dose of pembrolizumab and for at least 180 days after the last dose of chemotherapy.
        - Substudies 2 and 3: for at least 120 days after study treatment

*Substudies 1 and 2 Only:
Has not received prior systemic treatment for their metastatic NSCLC

*Substudy 2 Only:
Has a programmed death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥1%

*Substudy 3 Only:
- Has progressed on treatment with an anti-PD-(L)1 monoclonal antibody (mAb) administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies
- Has progressive disease during/after platinum doublet chemotherapy.

Criteri di esclusione: 

- Has a diagnosis of small cell lung cancer
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days before the first dose of study treatment
- Has a known additional malignancy that is progressing or has required active treatment within the past 2 years
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Has an active autoimmune disease that has required systemic treatment in the past 2 years
- Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
- Has an active infection requiring systemic therapy
- Has clinically significant cardiac disease, including unstable angina, acute myocardial infarction within 6 months from Day 1 of study treatment administration, or New York Heart Association Class III or IV congestive heart failure
- Has a known history of HIV infection
- Has a known history of Hepatitis B or known active Hepatitis C virus infection
- Has had major surgery <3 weeks before the first dose of study treatment
- Is expected to require any other form of antineoplastic therapy while on study
- Has received prior radiation therapy to the lung that is >30 Gray (Gy) within 6 months of the first dose of study treatment
- Has received a live vaccine within 30 days before the first dose of study treatment. Any licensed COVID-19 vaccine (including for Emergency Use) in a particular country is allowed as long as they are messenger ribonucleic acid (mRNA) vaccines, adenoviral vaccines, or inactivated vaccines. Investigational vaccines (ie, those not licensed or approved for Emergency Use) are not allowed
- Has received any prior immunotherapy and was discontinued from that treatment due to a severe or worse immune-related adverse event (irAE)
- Has had chemotherapy or biological cancer therapy within 4 weeks before the first dose of study treatment or has not recovered to Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or better from the AEs due to cancer therapeutics administered more than 4 weeks before the first dose of study treatment (including participants who had previous immunomodulatory therapy with residual irAEs)
- Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study treatment
- Previously had a severe hypersensitivity reaction to treatment with monoclonal antibodies (including pembrolizumab) and/or any of their excipients
- Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment
- Has had an allogenic tissue/solid organ transplant

*Substudy 1 Only:
- Has symptomatic ascites or pleural effusion (if receiving pemetrexed)
- Has a history or current evidence of a gastrointestinal (GI) condition (e.g. inflammatory bowel disease, Crohn's disease, ulcerative colitis) or impaired liver function or diseases that in the opinion of the investigator may significantly alter the absorption or metabolism of oral medications
- Is getting chemotherapy and has clinically active diverticulitis, intra-abdominal abscess, GI obstruction, or peritoneal carcinomatosis
- Has preexisting neuropathy that is moderate in intensity
- Is unable to interrupt aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs), other than aspirin dose less than or equal to 1.3 gm/day for a 5-day period (8-day period for long acting agents such as peroxicam), for participants who will receive pemetrexed
- Is unable or unwilling to take folic acid or vitamin B12 supplementation, for participants who will receive pemetrexed
Has a known sensitivity to any component of carboplatin, paclitaxel, pemetrexed or any of their excipients

*Substudies 1 and 2 Only:
- Has received prior systemic cytotoxic chemotherapy or other targeted or biological antineoplastic therapy for metastatic disease
- Has received prior therapy with an anti-programmed cell death-1 (PD-1), anti-programmed cell death-ligand 1 (PD-L1), or anti-PD-L2 agent or prior therapy targeting other immunoregulatory receptors or mechanisms

*Substudy 3 Only:
- Has received prior therapy targeting other immuno-regulatory receptors or mechanisms, not including anti-PD-(L)1 agents
- Has participated in Substudies 1 or 2.

Trattamento sperimentale: 

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) PLUS chemotherapy in combination with vibostolimab (MK-7684), MK-5890, or MK-4830 in treatment-naïve participants with advanced squamous or non-squamous NSCLC

Trattamento di controllo: 

NA

Note generali: 

This study is one of three pembrolizumab substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01)

Centri partecipanti

Nord Italia

Ospedale San Raffaele di Milano
Via Olgettina 60 - 20132 Milano - MI

Riferimento: Dr.ssa Francesca Ogliari
Email: ogliari.francesca@hsr.it

 

Centro Italia

AOU Careggi
Largo Brambilla 3 - 50134 Firenze - FI

Riferimento: Prof. Lorenzo Livi
Email: datamanager.gs.rt@sbsc.unifi.it

 

Fondazione Policlinico A. Gemelli
Largo Agostino Gemelli 8 - 00168 Roma - RM

Riferimento: Prof. Emilio Bria
Telefono: 0630154953
Email: emilio.bria@policlinicogemelli.it

Informazioni Generali

Protocollo

Numero di iscrizione a registro: 2020-001626-56

Data di inserimento: 13.05.2022

Promotore

Merck Sharp & Dohme LLC

CRO

/

Principal Investigator ITALIA

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma

Riferimento: Prof. Emilio Bria

Telefono: 0630154953

Email: emilio.bria@policlinicogemelli.it

Localita: Roma

 

<< Torna a "Tutti gli studi"

Apri